All You Need to Know About Twist Bioscience Rating Upgrade to Buy
| TWST Stock | USD 46.47 0.76 1.61% |
Slightly above 61% of Twist Bioscience's investor base is looking to short. The analysis of the overall investor sentiment regarding Twist Bioscience Corp suggests that many traders are alarmed. Twist Bioscience's investing sentiment can be driven by a variety of factors including economic data, Twist Bioscience's earnings reports, geopolitical events, and overall market trends.
Twist |
Twist Bioscience has been upgraded to a Zacks Rank 2 , reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Read at zacks.com
 |
Twist Bioscience Fundamental Analysis
We analyze Twist Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Twist Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Twist Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Twist Bioscience is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Twist Bioscience Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Twist Bioscience stock to make a market-neutral strategy. Peer analysis of Twist Bioscience could also be used in its relative valuation, which is a method of valuing Twist Bioscience by comparing valuation metrics with similar companies.
Peers
Twist Bioscience Related Equities
| CDNA | Caredx | 1.09 | ||||
| GH | Guardant Health | 0.33 | ||||
| MTD | Mettler Toledo | 0.31 | ||||
| TMO | Thermo Fisher | 0.27 | ||||
| ILMN | Illumina | 0.04 | ||||
| ICLR | ICON PLC | 0.03 | ||||
| WAT | Waters | 0.01 | ||||
| EXAS | EXACT Sciences | 0.02 | ||||
| CSTL | Castle Biosciences | 0.04 | ||||
| DHR | Danaher | 0.04 | ||||
| A | Agilent Technologies | 0.06 | ||||
| NTRA | Natera | 0.16 | ||||
| IQV | IQVIA Holdings | 0.48 | ||||
| PSNL | Personalis | 3.18 |
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.